Cargando...
Kinase Impaired BRAF Mutations Confer Lung Cancer Sensitivity to Dasatinib
During a clinical trial of the tyrosine kinase inhibitor dasatinib for advanced non–small cell lung cancer (NSCLC) one patient responded dramatically and remains cancer-free 4 years later. A comprehensive analysis of his tumor revealed a previously undescribed, kinase inactivating BRAF mutation ((Y4...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2012
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3836384/ https://ncbi.nlm.nih.gov/pubmed/22649091 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/scitranslmed.3003513 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|